Afatinib in combination with pembrolizumab in patients with Stage IIIB/IV squamous cell carcinoma of the lung
Benjamin Levy, Luis Paz-Ares, Jaafar Bennouna, Enriqueta Felip, Delvys Abreu, Dolores Isla, Fabrice Barlesi, Olivier Molinier, Jeannick Madelaine, Clarisse Audigier-Valette, Sang-We Kim, Hye Ryun Kim, Mustafa Ozguroglu, Mustafa Erman, Firas B Badin, Tarek Mekhail, Ronald J. Scheff, Michael J. Chisamore, Behbood Sadrolhefazi, Jonathan W. Riess
Learn more about the science behind this poster in the videos, papers and other materials below.
FOR HEALTHCARE PROFESSIONALS ONLY.
In the European Union, afatinib is approved for use in TKI-naive adults with locally advanced or metastatic NSCLC with activating EGFR mutations and in patients with NSCLC of squamous histology on or after chemotherapy. It is not yet approved in other indications.
Using this link will let you leave a website of Boehringer Ingelheim International GmbH (“BI”) or to a different domain under the control of BI. In the event that the linked site is not under the control of BI but under the control of a third party or an affiliate in the Boehringer Ingelheim group of companies, BI shall not be responsible for the contents, processing of personal data of any linked site or any link contained in a linked site, or any changes or updates to such sites. This link is provided to you only as a convenience, and the inclusion of any link does not imply endorsement by BI of the site.
Do you want to continue ?Continue